Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy. Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects. Here we designed two indomethacin analogues by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings. Both compounds were found to target AKR1C3 in a selective manner. In particular, hydroxyfurazan derivative is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes. High-resolution crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors. In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogues showed higher potency than indomethacin. Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.

Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3

Lolli, Marco L
First
;
Carnovale, Irene M;Pippione, Agnese C;Bonanni, Davide;Marini, Elisabetta;Zonari, Daniele;Gallicchio, Margherita;Boscaro, Valentina;Rolando, Barbara;Adinolfi, Salvatore;Oliaro-Bosso, Simonetta
Co-last
;
Boschi, Donatella
Co-last
2019

Abstract

Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy. Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects. Here we designed two indomethacin analogues by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings. Both compounds were found to target AKR1C3 in a selective manner. In particular, hydroxyfurazan derivative is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes. High-resolution crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors. In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogues showed higher potency than indomethacin. Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.
10
4
437-443
443
https://pubs.acs.org/doi/abs/10.1021%2Facsmedchemlett.8b00484
AKR1C3, Bioisosterism, Indomethacin, Prostate cancer, Scaffold hopping, X-ray crystallography
Lolli, Marco L; Carnovale, Irene M; Pippione, Agnese C; Wahlgren, Weixiao Y; Bonanni, Davide; Marini, Elisabetta; Zonari, Daniele; Gallicchio, Margherita; Boscaro, Valentina; Goyal, Parveen; Friemann, Rosmarie; Rolando, Barbara; Bagnati, Renzo; Adinolfi, Salvatore; Oliaro-Bosso, Simonetta; Boschi, Donatella
File in questo prodotto:
File Dimensione Formato  
REPRINT_acsmedchemlett.8b00484.pdf

Accesso riservato

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 1.65 MB
Formato Adobe PDF
1.65 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
2019-acsmedchemlett.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.65 MB
Formato Adobe PDF
1.65 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Lolli et al_AKR1C3_REVISED _submitted.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 600.9 kB
Formato Adobe PDF
600.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1700881
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact